Clinical Trial Update: Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3 [Phase 4]

View source ↗

Summary

This Phase 4 trial update investigates the mechanisms behind the hypotensive response to ARB/NEP inhibition in heart failure, and the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Entresto (sacubitril/valsartan)

Snippet

Sponsor: Yale University | Conditions: Heart Failure | Phase 4 | Status: COMPLETED